FDA declines to approve Cingulate's ADHD treatment over manufacturing issues

By Siddhi Mahatole June 2 (Reuters) - Drug developer Cingulate said on Tuesday the U.S. Food and Drug Administration declined ...

Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt ...
The American Journal of Managed Care

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

The CRL comes after the FDA accepted the NDA for review in October 2025 and set a Prescription Drug User Fee Act target ...
Fierce Pharma

ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection

After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate ...
Nature

Cingulate Cortex Function and Connectivity

The cingulate cortex occupies a medial position in the cerebral hemispheres and extends from the frontal lobe (anterior cingulate cortex, ACC) through the midcingulate region (MCC) to the ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Yahoo Finance

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to ...
Yahoo Finance

Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...